DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Mol Cancer. 2021 Oct 16;20(1):134. doi: 10.1186/s12943-021-01437-0.
No abstract available

Keywords: DDX3X mutation; Drug resistance; Hematolymphoid malignancy; Prognosis; Tumour metastasis.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor*
  • Cell Line, Tumor
  • Cyclin D1 / genetics
  • DEAD-box RNA Helicases / deficiency*
  • Disease Progression
  • Drug Resistance, Neoplasm / genetics*
  • Exome Sequencing
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / diagnosis
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / genetics*
  • Lymphoma, Large B-Cell, Diffuse / metabolism
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / genetics
  • Lymphoma, Non-Hodgkin / metabolism
  • Mitogen-Activated Protein Kinases / metabolism
  • Mutation
  • Prognosis
  • STAT3 Transcription Factor / metabolism

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Cyclin D1
  • Mitogen-Activated Protein Kinases
  • DDX3X protein, human
  • DEAD-box RNA Helicases